Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention

• Main Authors: Patel V (Author), Lin FJ (Author), Ojo O (Author), Rao S (Author), Yu S (Author), Zhan L (Author), Touchette DR (Author)
• Format: Book
• Published: Centro de Investigaciones y Publicaciones Farmaceuticas, 2014-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Prasugrel is recommended over clopidogrel in poor/intermediate CYP2C19 metabolizers with acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), reducing the risk of ischemic events. CYP2C19 genetic testing can guide antiplatelet therapy in ACS patients. Objec...